NEW YORK (GenomeWeb News) – CombiMatrix said today that its chromosomal microarray test for miscarriage analysis has received conditional approval from the New York State's Department of Health, allowing the company to begin testing patient samples from the state.

"Gaining the conditional license and ultimately the final approval to market and sell our [Product of Conception] test throughout New York is an important milestone for us that will allow us to broaden the market for our number one growth product," CEO Mark McDonough said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.